Eli Lilly beats Q3 2026 earnings, lifts full‑year revenue outlook to $91‑$92 B
Eli Lilly reported third‑quarter 2026 revenue of $24.4 billion, up 39% year‑over‑year, and earnings of $7.22 per share on a GAAP basis and $7.48 on a non‑GAAP basis. The company raised its full‑year 2026 revenue guidance to $91 billion‑$92 billion while trimming its adjusted EPS outlook to $35‑$36 per share because of $4.57 per share of acquisition‑related charges. Strong sales of Mounjaro ($10.72 billion) and Zepbound ($5.35 billion) drove the results, while the new obesity pill Foundayo generated $184 million.
Why it matters
The higher revenue forecast signals continued growth from the GLP‑1 franchise, which may support a bullish outlook for the stock. The lower EPS guidance reflects one‑time acquisition charges, reducing near‑term profit expectations despite the earnings beat.
Key facts
- 1Q3 2026 revenue was $24.4 billion, a 39% increase versus Q3 2025. prnewswire.com
- 2GAAP EPS for Q3 2026 was $7.22 per share; non‑GAAP EPS was $7.48 per share. prnewswire.com
- 3Full‑year 2026 revenue guidance was raised to $91 billion‑$92 billion. prnewswire.com
- 4Adjusted EPS guidance for 2026 was trimmed to $35.00‑$36.00 per share. prnewswire.com
- 5Acquisition‑related charges added $4.57 per share, offsetting a $4.07 improvement in underlying profit guidance. finance.yahoo.com
- 6Mounjaro sales in Q3 were $10.72 billion; Zepbound sales were $5.35 billion. finance.yahoo.com
Summary written by AlphAI AI Desk from 20 of 71 sources. Not investment advice. Figures are as stated by the linked sources.